Glenmark Pharmaceuticals and Canadian drug maker SaNOtize Research & Development Corp jointly announced the launch of their nitric oxide nasal spray, branded as FabiSpray in India, following the approval from Drug Controller General of India (DCGI). The nasal spray is for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark received manufacturing and marketing approval from the Indian drug regulator for the product as part of the accelerated approval process.